JP2010535830A - デュシェンヌ型筋ジストロフィーの治療用化合物の製造 - Google Patents
デュシェンヌ型筋ジストロフィーの治療用化合物の製造 Download PDFInfo
- Publication number
- JP2010535830A JP2010535830A JP2010520499A JP2010520499A JP2010535830A JP 2010535830 A JP2010535830 A JP 2010535830A JP 2010520499 A JP2010520499 A JP 2010520499A JP 2010520499 A JP2010520499 A JP 2010520499A JP 2010535830 A JP2010535830 A JP 2010535830A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- solvent
- production method
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- 150000001875 compounds Chemical class 0.000 title claims description 35
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 title abstract description 17
- 238000011282 treatment Methods 0.000 title abstract description 11
- 239000002904 solvent Substances 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 10
- 239000008096 xylene Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 8
- 238000007363 ring formation reaction Methods 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 6
- 239000003377 acid catalyst Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- 150000001414 amino alcohols Chemical class 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000006227 byproduct Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 1
- KSGCNXAZROJSNW-UHFFFAOYSA-N 5-ethylsulfonyl-2-naphthalen-2-yl-1,3-benzoxazole Chemical compound C1=CC=CC2=CC(C=3OC4=CC=C(C=C4N=3)S(=O)(=O)CC)=CC=C21 KSGCNXAZROJSNW-UHFFFAOYSA-N 0.000 abstract description 3
- 102000011856 Utrophin Human genes 0.000 description 20
- 108010075653 Utrophin Proteins 0.000 description 20
- 239000000047 product Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 210000003205 muscle Anatomy 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 108010069091 Dystrophin Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102000001039 Dystrophin Human genes 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 201000006938 muscular dystrophy Diseases 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 238000003468 luciferase reporter gene assay Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- -1 4-Me-2-pentanone Chemical compound 0.000 description 2
- 230000035495 ADMET Effects 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000010535 acyclic diene metathesis reaction Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 101150015424 dmd gene Proteins 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 1
- UPJVUFCLBYQKFH-UHFFFAOYSA-N 2-amino-4-ethylsulfonylphenol Chemical compound CCS(=O)(=O)C1=CC=C(O)C(N)=C1 UPJVUFCLBYQKFH-UHFFFAOYSA-N 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000035969 Genetic neuromuscular disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 238000003120 Steady-Glo Luciferase Assay System Methods 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000013216 cat model Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 229960001987 dantrolene Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 238000011774 genetically engineered animal model Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000002961 luciferase induction Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000010198 maturation time Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 210000000518 sarcolemma Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0715937.9A GB0715937D0 (en) | 2007-08-15 | 2007-08-15 | Method of treatment og duchenne muscular dystrophy |
| PCT/EP2008/006719 WO2009021749A2 (en) | 2007-08-15 | 2008-08-14 | Preparation of a compound for the treatment of duchenne muscular dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2010535830A true JP2010535830A (ja) | 2010-11-25 |
Family
ID=38566447
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520499A Pending JP2010535830A (ja) | 2007-08-15 | 2008-08-14 | デュシェンヌ型筋ジストロフィーの治療用化合物の製造 |
| JP2010520498A Pending JP2010535829A (ja) | 2007-08-15 | 2008-08-14 | デュシェンヌ型筋ジストロフィーの治療用の化合物の多形体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520498A Pending JP2010535829A (ja) | 2007-08-15 | 2008-08-14 | デュシェンヌ型筋ジストロフィーの治療用の化合物の多形体 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20090048314A1 (enExample) |
| EP (2) | EP2176246A2 (enExample) |
| JP (2) | JP2010535830A (enExample) |
| KR (1) | KR20100075777A (enExample) |
| CN (2) | CN101896475A (enExample) |
| AR (1) | AR068810A1 (enExample) |
| AU (2) | AU2008286325A1 (enExample) |
| BR (2) | BRPI0811315A2 (enExample) |
| CA (2) | CA2685939A1 (enExample) |
| CL (1) | CL2008002391A1 (enExample) |
| GB (1) | GB0715937D0 (enExample) |
| IL (1) | IL201908A0 (enExample) |
| MX (2) | MX2009011967A (enExample) |
| PE (1) | PE20090604A1 (enExample) |
| RU (1) | RU2009141831A (enExample) |
| TW (1) | TW200911767A (enExample) |
| WO (2) | WO2009021748A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017175842A1 (ja) * | 2016-04-07 | 2017-10-12 | 国立大学法人京都大学 | スプライシングの改変に関する化合物及び医薬組成物 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2641880C (en) * | 2006-02-10 | 2014-09-09 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| GB201208178D0 (en) | 2012-05-10 | 2012-06-20 | Summit Corp Plc | Pharmaceutical composition for the treatment of duchenne muscular dystrophy |
| GB201412010D0 (en) | 2014-07-04 | 2014-08-20 | Summit Corp Plc | Treatment of hypertransaminasemia |
| WO2017168151A1 (en) | 2016-03-30 | 2017-10-05 | Summit (Oxford) Limited | Composition for the treatment of duchenne muscular dystrophy |
| KR102019048B1 (ko) | 2017-02-06 | 2019-09-09 | 가톨릭대학교 산학협력단 | MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법 |
| KR101886788B1 (ko) | 2017-02-07 | 2018-08-09 | 가톨릭대학교 산학협력단 | MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법 |
| EP3641741B1 (en) | 2017-06-19 | 2024-03-20 | University of Maryland, Baltimore | Microtubule polymerization inhibitor prodrugs and methods of using the same |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3993659A (en) * | 1971-08-10 | 1976-11-23 | Ciba-Geigy Corporation | Bis-benzoxazolyl-naphthalenes as optical brighteners |
| CH617809GA3 (enExample) * | 1975-10-10 | 1980-06-30 | ||
| US4110246A (en) * | 1976-05-13 | 1978-08-29 | Hoechst Aktiengesellschaft | Mixture of benzoxazole derivatives |
| DE3027479A1 (de) * | 1980-07-19 | 1982-03-04 | Hoechst Ag, 6000 Frankfurt | Mischungen von optischen aufhellern und deren verwendung |
| JPS615071A (ja) * | 1984-06-15 | 1986-01-10 | Fuji Photo Film Co Ltd | ベンゾオキサゾ−ル誘導体 |
| DE3617451A1 (de) * | 1986-05-23 | 1987-11-26 | Hoechst Ag | Sulfonat- oder sulfonamidgruppen-haltige bis-benzoxazolylnaphthaline, verfahren zu deren herstellung und deren verwendung |
| DE3819051A1 (de) * | 1988-06-04 | 1989-12-07 | Agfa Gevaert Ag | Farbfotografisches aufzeichnungsmaterial |
| EP0527704B1 (de) * | 1991-08-08 | 1996-08-28 | Ciba-Geigy Ag | Farbstoffe, Verfahren zu deren Herstellung und deren Verwendung |
| DE59509233D1 (de) * | 1994-02-24 | 2001-06-13 | Haarmann & Reimer Gmbh | Kosmetische und dermatologische zubereitungen, enthaltend phenylen-1,4-bisbenzimidiazolesulfonsäuren |
| US6004719A (en) * | 1994-04-25 | 1999-12-21 | Polaroid Corporation | Imaging medium and process for producing an image |
| BR9508177A (pt) * | 1994-06-30 | 1997-09-02 | Minnesota Mining & Mfg | Material de impressão dental e processo para monitorar a cura do mesmo |
| DE69532472T2 (de) * | 1994-06-30 | 2004-10-28 | Minnesota Mining And Mfg. Co., Saint Paul | Die härtung anzeigende form- und beschichtungsmasse |
| US6222044B1 (en) * | 1995-03-20 | 2001-04-24 | The Dow Chemical Company | Process for making 2-aryl benz (ox, thi, imid) azoles and 2-aminoaryl aminobenz (ox, thi, imid) azoles |
| US5567843A (en) * | 1995-03-20 | 1996-10-22 | The Dow Chemical Company | Process for making 2-aryl benz (ox, thi, imid)azoles and 2-aminoaryl aminobenz(ox, thi, imid)azoles |
| US5977101A (en) * | 1995-06-29 | 1999-11-02 | Smithkline Beecham Corporation | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity |
| US5645948A (en) * | 1996-08-20 | 1997-07-08 | Eastman Kodak Company | Blue organic electroluminescent devices |
| US5914213A (en) * | 1996-11-27 | 1999-06-22 | Polaroid Corporation | Process and composition for generation of acid |
| US6110638A (en) * | 1996-11-27 | 2000-08-29 | Polaroid Corporation | Process and composition for generation of acid |
| US6177572B1 (en) * | 1997-08-20 | 2001-01-23 | Sepracor, Inc. | Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use |
| US6312822B1 (en) * | 1998-05-28 | 2001-11-06 | Eastman Chem Co | Dispersion aids for optical brighteners in polyolefins |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| US6436558B1 (en) * | 1998-08-07 | 2002-08-20 | Fuji Photo Film Co., Ltd. | Organic electroluminescence element |
| FR2789582B1 (fr) * | 1999-02-12 | 2001-05-04 | Oreal | Compositions photoprotectrices contenant un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle |
| FR2789581B1 (fr) * | 1999-02-12 | 2001-05-04 | Oreal | Compositions photoprotectrices contenant un derive de benzotriazole, un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle |
| AU4562000A (en) * | 1999-05-07 | 2000-11-21 | Basf Aktiengesellschaft | 4-(3',4'-heterocyclyl benzoyl) pyrazoles as herbicidal agents |
| WO2000068210A1 (de) * | 1999-05-07 | 2000-11-16 | Basf Aktiengesellschaft | Benzohetero cyclylcyclo hexenone und ihre verwendung als herbizide |
| FR2794645B1 (fr) * | 1999-06-08 | 2001-08-10 | Oreal | Compositions photoprotectrices contenant un compose hydrocarbone bis-hydroxyphenylbenzotriazole et un compose a groupements benzoazolyle ou benzodiazolyle |
| DE60018194T2 (de) * | 1999-09-24 | 2006-01-05 | Ono Pharmaceutical Co. Ltd. | Hydroxamsäurederivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven wirkstoff enthalten |
| US6565987B2 (en) * | 1999-11-12 | 2003-05-20 | Eastman Chemical Company | Non-exuding optically brightened polyolefin blends |
| US6716413B1 (en) * | 2000-10-16 | 2004-04-06 | Mallinckrodt, Inc. | Indole compounds as tissue-specific exogenous optical agents |
| KR100750756B1 (ko) * | 2000-11-30 | 2007-08-20 | 캐논 가부시끼가이샤 | 발광 소자 및 표시 장치 |
| US20050261298A1 (en) * | 2002-01-18 | 2005-11-24 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
| US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| CA2476594C (en) * | 2002-03-05 | 2012-10-09 | Transtech Pharma, Inc. | Mono-and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| EP1547996A4 (en) * | 2002-08-30 | 2006-08-02 | Bf Res Inst Inc | DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES IN WHICH PRION PROTEIN IS ACCUMULATED, AND ANIMAL FEVERING FOR PRION PROTEIN |
| CA2523808A1 (en) * | 2003-05-16 | 2004-12-23 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
| MXPA05012350A (es) * | 2003-05-20 | 2006-05-25 | Transtech Pharma Inc | Antagonistas rage como agentes para la amiloidosis inversa y enfermedades asociadas con la misma. |
| SG146624A1 (en) * | 2003-09-11 | 2008-10-30 | Kemia Inc | Cytokine inhibitors |
| CN1882879B (zh) * | 2003-09-22 | 2010-08-11 | 爱克发印艺公司 | 可光聚合的组合物 |
| US7097888B2 (en) * | 2003-12-15 | 2006-08-29 | Eastman Kodak Company | Aligned liquid crystal layer containing azolium salts and process for increasing the tilt |
| US7592373B2 (en) * | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
| CA2555313A1 (en) * | 2004-02-06 | 2005-08-18 | Insight Biopharmaceuticals Ltd | Heparanase inhibitors and uses thereof |
| MY144903A (en) * | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
| JP2008510312A (ja) * | 2004-08-19 | 2008-04-03 | エルジー・ケム・リミテッド | バッファ層を含む有機発光素子およびその製作方法 |
| US7723340B2 (en) * | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| CN101142194B (zh) * | 2005-03-14 | 2012-10-10 | 顶点制药有限责任公司 | 吲哚衍生物，组合物及用作β-分泌酶抑制剂的方法 |
| JP2007086165A (ja) * | 2005-09-20 | 2007-04-05 | Fujifilm Corp | 感光性組成物、これを用いた平版印刷版原版及び画像記録方法 |
| EP1960078B1 (en) * | 2005-12-02 | 2014-03-12 | Sachem, Inc. | Anion-exchange displacement chromatography process |
| KR101213485B1 (ko) * | 2006-01-27 | 2012-12-18 | 삼성디스플레이 주식회사 | 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자 |
| KR101213486B1 (ko) * | 2006-02-02 | 2012-12-20 | 삼성디스플레이 주식회사 | 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자 |
| CA2641880C (en) * | 2006-02-10 | 2014-09-09 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| KR101325062B1 (ko) * | 2006-05-19 | 2013-11-05 | 삼성디스플레이 주식회사 | 발광 이종 핵 구리-이리듐 착체 및 이를 이용한 유기 전계발광 소자 |
-
2007
- 2007-08-15 GB GBGB0715937.9A patent/GB0715937D0/en not_active Ceased
-
2008
- 2008-08-14 RU RU2009141831/04A patent/RU2009141831A/ru not_active Application Discontinuation
- 2008-08-14 CN CN2008800158003A patent/CN101896475A/zh active Pending
- 2008-08-14 BR BRPI0811315-7A2A patent/BRPI0811315A2/pt not_active Application Discontinuation
- 2008-08-14 US US12/192,053 patent/US20090048314A1/en not_active Abandoned
- 2008-08-14 CA CA002685939A patent/CA2685939A1/en not_active Abandoned
- 2008-08-14 KR KR1020097023605A patent/KR20100075777A/ko not_active Withdrawn
- 2008-08-14 EP EP08785565A patent/EP2176246A2/en not_active Withdrawn
- 2008-08-14 MX MX2009011967A patent/MX2009011967A/es not_active Application Discontinuation
- 2008-08-14 WO PCT/EP2008/006718 patent/WO2009021748A2/en not_active Ceased
- 2008-08-14 AU AU2008286325A patent/AU2008286325A1/en not_active Abandoned
- 2008-08-14 AR ARP080103560A patent/AR068810A1/es not_active Application Discontinuation
- 2008-08-14 US US12/599,970 patent/US8138351B2/en not_active Expired - Fee Related
- 2008-08-14 CN CN200880015864A patent/CN101679323A/zh active Pending
- 2008-08-14 CL CL2008002391A patent/CL2008002391A1/es unknown
- 2008-08-14 MX MX2009011916A patent/MX2009011916A/es not_active Application Discontinuation
- 2008-08-14 CA CA002685590A patent/CA2685590A1/en not_active Abandoned
- 2008-08-14 PE PE2008001385A patent/PE20090604A1/es not_active Application Discontinuation
- 2008-08-14 JP JP2010520499A patent/JP2010535830A/ja active Pending
- 2008-08-14 EP EP08785566A patent/EP2188270A2/en not_active Withdrawn
- 2008-08-14 JP JP2010520498A patent/JP2010535829A/ja active Pending
- 2008-08-14 AU AU2008286324A patent/AU2008286324A1/en not_active Abandoned
- 2008-08-14 WO PCT/EP2008/006719 patent/WO2009021749A2/en not_active Ceased
- 2008-08-14 TW TW097131010A patent/TW200911767A/zh unknown
- 2008-08-14 BR BRPI0811548-6A2A patent/BRPI0811548A2/pt not_active Application Discontinuation
-
2009
- 2009-11-03 IL IL201908A patent/IL201908A0/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017175842A1 (ja) * | 2016-04-07 | 2017-10-12 | 国立大学法人京都大学 | スプライシングの改変に関する化合物及び医薬組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL201908A0 (en) | 2010-06-16 |
| AU2008286324A1 (en) | 2009-02-19 |
| BRPI0811315A2 (pt) | 2015-01-27 |
| WO2009021748A3 (en) | 2009-04-02 |
| CN101896475A (zh) | 2010-11-24 |
| PE20090604A1 (es) | 2009-05-16 |
| CL2008002391A1 (es) | 2009-05-22 |
| CA2685590A1 (en) | 2009-02-19 |
| MX2009011967A (es) | 2009-11-19 |
| RU2009141831A (ru) | 2011-05-20 |
| WO2009021749A3 (en) | 2009-04-02 |
| US8138351B2 (en) | 2012-03-20 |
| US20100267961A1 (en) | 2010-10-21 |
| CA2685939A1 (en) | 2009-02-19 |
| US20090048314A1 (en) | 2009-02-19 |
| AU2008286325A1 (en) | 2009-02-19 |
| JP2010535829A (ja) | 2010-11-25 |
| WO2009021748A2 (en) | 2009-02-19 |
| AR068810A1 (es) | 2009-12-09 |
| WO2009021749A8 (en) | 2009-09-11 |
| WO2009021749A2 (en) | 2009-02-19 |
| KR20100075777A (ko) | 2010-07-05 |
| GB0715937D0 (en) | 2007-09-26 |
| TW200911767A (en) | 2009-03-16 |
| BRPI0811548A2 (pt) | 2014-11-18 |
| EP2176246A2 (en) | 2010-04-21 |
| MX2009011916A (es) | 2009-11-18 |
| EP2188270A2 (en) | 2010-05-26 |
| CN101679323A (zh) | 2010-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8138351B2 (en) | Treatment of duchenne muscular dystrophy | |
| US20120149741A1 (en) | Treatment of duchenne muscular dystrophy | |
| Huang et al. | A robust TDP-43 knock-in mouse model of ALS | |
| JP5808797B2 (ja) | 筋萎縮を阻害するための方法 | |
| EP2170396B1 (en) | Drug combinations for the treatment of duchenne muscular dystrophy | |
| JP4018884B2 (ja) | 脊柱筋萎縮症の治療 | |
| WO2008029168A2 (en) | Treatment of duchenne muscular dystrophy | |
| US20100048660A1 (en) | Treatment of duchenne muscular dystrophy | |
| EP4046657A1 (en) | Application of tpk as a target in alzheimer's disease | |
| Suzuki et al. | The carboxy-terminus of p63 links cell cycle control and the proliferative potential of epidermal progenitor cells | |
| Chen et al. | Cloning and expression of P450c17-I (17α-hydroxylase/17, 20-lyase) in brain and ovary during gonad development in Cynoglossus semilaevis | |
| WO2010119194A1 (fr) | Dérivés d'imidazolidine-2,4-dione et leur utilisation comme médicament | |
| Banks et al. | Loss of symmetric cell division of apical neural progenitors drives DENND5A-related developmental and epileptic encephalopathy | |
| WO2021160012A1 (zh) | 一种特异性降解tau蛋白的小分子化合物及其用途 | |
| Losby et al. | The Estrogen Receptor-Related Orphan Receptors Regulate Autophagy through TFEB | |
| CA3176384A1 (en) | Method of treating ship1-mediated diseases using pelorol derivatives | |
| Jiang et al. | Expression profile of Chchd10 gene during testicular development | |
| CN115851745B (zh) | 调控Esrrb活性的物质在制备用于干预视网膜劈裂症的产品中的应用 | |
| Costigan | Investigating the Role of Mitochondrial Metabolism in Human Kidney Development and Maldevelopment | |
| Zhang et al. | Ablation of Tmem65 Causes Lethal Mitochondrial Encephalomyopathy in Mouse | |
| Berchowitz et al. | The Retrotransposon-Derived Capsid Genes PNMA1 and PNMA4 Maintain Reproductive Capacity | |
| Das et al. | Autosomal Dominant Polycystic Kidney Disease: At a Glance | |
| CN120607578A (zh) | 17β-HSD1抑制剂化合物、药物组合物及其应用 | |
| Ho | Understanding the Moonlighting Functions of Glycerol Kinase | |
| Bennett | The role of RNA helicases in neuromuscular development and diseases |